KLOX Technologies Announces European CE Mark Approval for its Innovative, Non-Invasive Acne Vulgaris Product

Laval, Quebec (ots/PRNewswire) -

LumiCleanse[TM]is a clinically-proven treatment now available for
all severities of acne vulgaris developed by KLOX in Canada, destined
for the global acne market

KLOX Technologies Inc. ("KLOX" or the "Company") is pleased to
announce that it has received CE mark approval in Europe for its
topical photo-converter gel as a Class IIa Medical Device for the
treatment of acne vulgaris, including all severities. The gel is part
of KLOX's LumiCleanse[TM] System, a first-in-class innovative,
non-invasive acne vulgaris treatment with a clinically-proven
superior safety and efficacy profile. The LumiCleanse[TM] System was
previously approved for the treatment of all severities of acne
vulgaris in Canada in September of this year.

"We are pleased to reach another significant milestone in our
regulatory and commercial roadmap and in our efforts to expand the
reach of KLOX's innovative treatment in the $3 billion global acne
market. Europe represents a significant pool of potential patients
with unmet needs when it comes to the effective treatment of mild to
severe acne," stated Dr. Lise Hébert, President and CEO of KLOX.

The clinical evidence for the medical device application was based
on a European registration trial conducted in Europe. In the study,
the system demonstrated effectiveness in moderate to severe acne
vulgaris patients and was clinically and statistically significant on
the primary (p < 0.0001) and all of the secondary endpoints, with an
extremely favourable safety profile. The three month extension study
demonstrated a similar effectiveness and safety profile. The
persistence of effect was maintained in 92% of the cohort who had met
the primary efficacy endpoint in the registration trial, thus
demonstrating a persistence of effect of at least 6 months.

About Acne Vulgaris Acne vulgaris is a chronic disease that can
have devastating physical, social and psychological effects on those
who suffer from it, particularly in moderate to severe cases. Acne
vulgaris affects over 150 million people worldwide. It accounts for
over 30% of dermatology visits and over 40% of those suffering from
this disease are looking for treatments with a better safety and
efficacy profile than what is currently available. Many of the
topical, oral and light-based treatments for acne vulgaris are
characterized by inconsistent efficacy/persistence, systemic
treatment schedules, problems with patient tolerability and in most
cases, side-effects.

About LumiCleanse[TM]System The LumiCleanse[TM] System is
comprised of a multi-LED light, which activates a topical
photo-converter gel applied on the affected area to achieve safe and
efficacious results in the treatment of acne vulgaris. This is done
by targeting the underlying problems that lead to acne vulgaris as
well as stimulating collagen in traumatized skin. The system is
designed to promote healing in both the epidermis and deeper in the
dermis in a non-invasive manner. Completed within a 15-minute
treatment cycle including preparation, the treatment requires
applications twice a week for a six-week period. The technology is
non-abrasive, non-thermal, and is comfortable for the patient.

About KLOX Technologies: Leveraging multi-indication Biophotonic
platform Based in Laval, Quebec, KLOX is a privately-owned company
focused on the development of a unique, non-invasive patent-protected
biophotonic platform using a primary device consisting of a multi-LED
lighting system that interacts with an oxygen-rich gel containing
light-trapping molecules. KLOX's cosmetics and medical devices are
destined for the rapidly growing cosmetic, dermatological, and tissue
repair markets.

For further information on KLOX, please visit the Company's
website: http://www.kloxtechnologies.com.

Forward Looking Statements

Certain statements contained in this presentation, other than
statements of fact that are independently verifiable at the date
hereof, may constitute forward-looking statements. Examples of such
forward looking statements include those regarding cosmetics and
medical devices and medical applications and clinical trials and the
status and related results thereto, as well those regarding
continuing and further development efforts. Such statements, based as
they are on the current analysis and expectations of management,
inherently involve numerous risks and uncertainties, known and
unknown, many of which are beyond KLOX Technologies Inc.'s control.
Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the medical, cosmetics
and/or consumer goods industries, changes in the regulatory
environment in the jurisdictions in which KLOX Technologies Inc. does
business, financial and commercial markets volatility, fluctuations
in costs, and changes to the competitive environment, as well as
other risks. Consequently, actual future results may differ
materially from the anticipated results expressed in the
forward-looking statements. In the case of forward-looking statements
regarding investigational product candidates and continuing and
further development efforts, specific risks which could cause actual
results to differ materially from KLOX Technologies Inc.'s current
analysis and expectations include: failure to demonstrate the safety,
tolerability and efficacy of our products, final and quality
controlled verification of data and the related analyses, and the
expense and uncertainty of obtaining regulatory approval.

For further information:

Roch Landriault
NATIONAL Public Relations
+1(514)843-2345

Geneviève Hinse
NATIONAL Public Relations
+1(514)843-2304

ots Originaltext: Klox Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.de